Evaluation of cardiovascular complications with <sup>99m</sup>Tc tetrofosmin gated myocardial perfusion scintigraphy in patients with thalassemia major
GEDIK G, ÇAGLAR M, ÜNAL S, GÜMRÜK F
Revista Española de Medicina Nuclear e Imagen Molecular 2008;27(3): 191-198
Resumen del Autor:
Objective. Iron overload limits the life expectancy of thalassaemic patients by causing cardiac toxicity. Iron also plays a catalytic role in the pathogenesis of atherosclerosis. The aim of this study was to evaluate the role of 99mTc Tetrofosmin gated myocardial perfusion scintigraphy (GMPS) in the detection of cardiac dysfunction in patients with thalassemia major. Materials and methods. Forty two patients with homozygous beta-thalassemia were enrolled in the study. Myocardial perfusion and wall motion were analysed in all patients (mean age 17 ± 5.28) and 34 age-matched controls using GMPS. Clinical data, liver function tests, hemoglobin, ferritin, low density lipoprotein (LDL) and cholesterol levels, and the total number and frequency of transfusions were collected from patient records. Results. 97.6 % and 78.5 % of patients had normal myocardial perfusion and wall motion respectively. Nine out of 42 thalassaemic patients had abnormal left ventricular wall motion; half of these
had septal hypokinesia. No significant correlation was found between the total number of transfusions, serum ferritin levels and left ventricular ejection fraction (p = 0.442 and p = 1.00, respectively). Echocardiography revealed systolic dysfunction in 5 out of 9 patients with wall motion abnormality. LDL was normal in 38 out of 42 patients and cholesterol levels were normal in 37 out of 42 patients. Conclusions. Regional wall motion abnormalities can be seen in patients with thalassemia major. This early damage is frequently located in the septum and can be detected by GMPS. Serum ferritin levels and the number of blood transfusions are inadequate as predictors of myocardial dysfunction.
* RECUERDE. Al pulsar el enlace “Texto completo”, usted abandonará el entorno MEDES. En ese caso, la web a la que desea acceder no es propiedad de Fundación Lilly y, por tanto, ésta no se responsabiliza de los contenidos, informaciones o servicios presentes en ella, ni de la política de privacidad que aplique el sitio web de un tercero.